As a mono-therapy these group of necroptosis regulators could be ineffective in tumors that downregulate the level of RIPK3 or MLKL, but these medicines may increase the effect of the above listed mediators in combination therapy following the restoration of RIPK1 or RIPK3 expression in cancer cells. Here, MLKL is linked to cancer.